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Background: Post-translational modifications (PTMs) constitute a major aspect of protein biology, particularly
signaling events. Conversely, several different pathophysiological PTMs are hallmarks of oxidative imbalance or
inflammatory states and are strongly associated with pathogenesis of autoimmune diseases or cancers. Accordingly,
it is of interest to assess both the biological and structural effects of modification. For the latter, computer-based
modeling offers an attractive option. We thus identified the need for easily applicable modeling options for PTMs.
Results: We developed PyTMs, a plugin implemented with the commonly used visualization software PyMOL.
PyTMs enables users to introduce a set of common PTMs into protein/peptide models and can be used to address
research questions related to PTMs. Ten types of modification are currently supported, including acetylation,
carbamylation, citrullination, cysteine oxidation, malondialdehyde adducts, methionine oxidation, methylation,
nitration, proline hydroxylation and phosphorylation. Furthermore, advanced settings integrate the pre-selection of
surface-exposed atoms, define stereochemical alternatives and allow for basic structure optimization of the newly
modified residues.
Conclusion: PyTMs is a useful, user-friendly modelling plugin for PyMOL. Advantages of PyTMs include standardized
generation of PTMs, rapid time-to-result and facilitated user control. Although modeling cannot substitute for
conventional structure determination it constitutes a convenient tool that allows uncomplicated exploration of
potential implications prior to experimental investments and basic explanation of experimental data. PyTMs is
freely available as part of the PyMOL script repository project on GitHub and will further evolve.
Keywords: Post-translational modifications, PyMOL plugin, Structural bioinformatics, Modeling, Acetylation,
Carbamylation, Citrullination, Oxidations, Malondialdehyde adducts, NitrationBackground
Post-translational modifications
Post-translational modifications (PTMs) are chemical al-
terations that occur after protein synthesis [1,2]. Physio-
logically, PTMs are selectively introduced by specific,
dynamically-regulated enzymes in order to alter the tar-
get protein’s biochemical properties. PTMs are thus
employed to regulate biological processes by altering, for
example, protein activity, signaling, localization, con-
formation, binding or turnover [3-5]. The involvement of
PTMs in cellular signaling cascades, particularly kinase-
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unless otherwise stated.Conversely, pathophysiological PTMs are associated
with episodes of oxidative imbalance, and there is a
constant cellular endeavor to prevent and repair their
occurrence. Unlike physiological PTMs, pathophysio-
logical PTMs typically occur in proximity to the origin
of the modifying agent in an uncontrolled fashion. The
formation of such pathophysiological PTM on their tar-
get proteins may impinge on cellular homeostasis and
immune recognition [3-8]. Smoking in particular has
been identified as a risk factor with respect to PTMs
and inflammation [9-11]. Due to altered immunogen-
icity and the associated inflammation, pathophysio-
logical PTMs are of particular interest in the context of
autoimmune pathogenesis [3-5]. Conversely, the PTM-
mediated altered immunogenicity of proteins has been
suggested as a means of escape from immune surveil-
lance in cancer [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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its carrier protein is highly individual and context-
dependent [3,4,12,13]. Regarding a protein’s activity,
modification can be regulatory, resulting in either gain-
or loss-of-function, or alternatively have no immediate
effect - depending largely on the location of the PTM.
The latter is argued to have been evolutionarily selected
for in the context of Methionine oxidation, in particular
in mitochondrial enzymes, because oxidation of the dis-
tal ‘scavenger’ residues protects critical functional sites
[14]. Taken together, this highlights the relevance of
structural positioning in regard to PTMs.
There are accumulating examples of specific PTMs
being recognized by scavenger receptors, complement
components and antibodies due to alterations in struc-
ture and charge [12,15-17]. One sensible biological
function is the accelerated disposal of damaged pro-
teins. Conversely, a classic example is the accumulation
of ‘foam cells’ in atherosclerotic plaques. These are
macrophages that have accumulated oxidized low dens-
ity lipoprotein due to increased uptake mediated by the
scavenger receptor CD36 [16]. More recently, comple-
ment factor H (CFH) has been demonstrated to be in-
volved in the disposal of oxidatively modified proteins
bearing adducts jointly formed by Malondialdehyde
(MDA) and Acetaldehyde (MAA-adduct) [15]. MDA is
a highly reactive three-carbon dialdehyde formed dur-
ing lipid peroxidation. A polymorphism in CFH (HIS
instead of TYR at residue 402) is argued to result in a
reduced clearance of damaged MAA-modified proteins
in the eye, with causative links to age-related macular
degeneration [15]. Interestingly, native antibodies from
newborns appear to recognize the same modification
[17]. The structural nature of this and other such inter-
actions, however, remain to be characterized in detail.
The antigenicity of complement-bound antigen has
been demonstrated to increase by several orders of
magnitude, as evidenced by co-ligation of the B cell re-
ceptor and CD19 bridged by complement component
C3dg [18]. This agrees with the reported antigenicity of
MDA-adducted proteins [19,20], provided that pro-
inflammatory complement components recognize PTMs
and thus ‘flag’ them for increased immune surveillance.
Furthermore, MDA has been experimentally implied in
the pathogenesis of animal models of Multiple Sclerosis
(MS) [5,21], and there is clinical evidence of elevated lipid
peroxidation as a source of MDA in MS patients [22,23].
In fact, most autoimmune diseases have an implied
involvement of PTMs, and associated altered peptide li-
gands (APLs) have been identified [3-5,24,25]. A com-
mon mechanistic denominator in autoimmunity (or
allergy) is the absence of negative selection of T or B
cells during education. Such non-tolerized, cross-reactive
clones, capable of recognizing ‘modified self ’ or ‘crypticepitopes’, are suspected to initiate the break of immuno-
logical tolerance [3,4]. The key underlying molecular
events are the processing of the non-tolerized epitope for
presentation, and finally the recognition of this peptide
presented within a matching Major Histocompatibility
Complex (MHC) by a cross- and/or self-reactive T cell re-
ceptor (TCR).
In Rheumatoid Arthritis there is a strong association
of specific MHC alleles and their ability to present
citrullinated APLs, i.e. epitopes that have undergone
enzymatic deimination of arginine residues to citrulline.
The molecular basis of this association has only re-
cently been characterized at a structural level [25].
There are accumulating examples of APLs being either
superior or inferior epitopes in the context of MHC
presentation or TCR recognition [12,24,25]. Taken to-
gether, these emphasize the requirement for individual
structural assessment in the context of immunology
and PTMs.
In conclusion, PTMs constitute a complex layer in pro-
tein biology and immune recognition. The diversity and
context-dependence of PTM-mediated effects calls for in-
dividual assessment at a structural level. Furthermore, we
identify an unmet need for easily applicable modeling
tools in respect to PTMs.
Post-translational modifications in protein models
As outlined above, it is of increasing interest for re-
searchers to assess the potential impact of PTMs of par-
ticular proteins, or to provide structural insight into how
an introduced PTM potentially can exert an experimen-
tally observed effect. Recent advances in accounting for
PTMs during resolution of 3D structures have been
made [26]. However, resolving a 3D-structure may prove
unattractive or infeasible due to financial, technical or
time-related reasons. In this case, modeling the PTM in
silico provides a rapid alternative. The online resource
PhosphoSitePlus (http://www.phosphosite.org/) [27] is
able to indicate relevant sites in proteins by mining data-
base entries, but does not include or introduce the PTM
unless it is already present in an existing crystal struc-
ture. To our knowledge, no simple, freely available tool
is available that can easily perform such a task. Manual
structure editing is conceivable using the visualization
software PyMOL (http://www.pymol.org/), but is likely
time-consuming and will thus not provide good flexibil-
ity for various models. We therefore developed PyTMs
as an applicable PyMOL plugin that enables the straight-
forward introduction and modeling of a set of PTMs into
existing 3D-structures. PyMOL is commonly used, easy to
handle and freely available. Advantages of using automated
PTM creation include: firstly, standardized and reprodu-
cible PTMs; secondly, minimal time-requirement; thirdly,
availability of the option to a broader user audience.
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egories which are summarized in Figure 1, namely
acetylation [8,28,29], carbamylation [9], citrullination
[25], cysteine oxidation [30], malondialdehyde adducts
[10,11,16,31-36], methionine oxidation [37,38], methy-
lation [39], nitration [6,12-14], proline hydroxylation
[40,41] and phosphorylation [42].
Implementation
PyTMs implementation notes
We implemented PyTMs as a plugin for the PyMOL
Molecular Graphics System (Schrödinger, LLC., http://
www.pymol.org/). The name PyTMs has been chosen
as an analogy to PyMOL, Python (https://www.python.
org/) and PTMs. PyTMs is written in Python and is
open source: the file is freely available as part of the
PyMOL script repository, allowing version control and
updating (visit http://www.pymolwiki.org/index.php/
Pytms for more information). The first release version is
provided as Additional file 1. PyTMs is designed to fa-
cilitate the introduction of post-translational modifica-
tions into existing 3D-structure models. The intention is
to provide a simple research tool that allows making
predictions and explaining observations associated with
PTMs, yet requiring only basic PyMOL user experience.
For this reason we also provided a convenient user inter-
face (cf. Additional file 2).
PyTMs conception
PyTMs allows modeling of a selected set of common
modifications. We used RCSB database (http://www.
rcsb.org/) entries containing modified residues as tem-
plates where available. Furthermore, the nomenclature
of modified residues was adjusted to correspond to this
database as far as possible. More detailed information
on the implementation of certain PTMs is available in
Additional file 3. Though PyTMs employs basic struc-
ture editing options already available in PyMOL, the ad-
vantage of using PyTMs is the automation of the
process, which enables basic users to edit any structure
within seconds and currently does not depend on a
library.
Basic algorithm
The basic algorithm of PyTMs follows a pattern that is
similar for each individual PTM. First, the input selec-
tion is broken down to filter candidate amino acids as
determined by the class of PTM and settings. If selected,
this will involve a pre-selection of surface-exposed resi-
dues, based on a provided solvent-accessible area cutoff
(in Å2). The subsequent sub-selection of target atoms
for modification is automatic, thus the user does not
need to provide a specific selection, apart from the ob-
ject or atom group. Selections or objects can also bechosen from the integrated menu. The candidate resi-
dues are filtered for existing modifications and se-
quentially modified, renamed, adjusted and optionally
colored.
For some PTMs, e.g. Malondialdehyde adducts, we im-
plemented a residue-based basic structure optimization.
This optimization avoids steric Van-der-Waals (vdW)
clashes by rotating the residue into a favorable position.
The calculated vdW strain is minimized in the process.
For reduction of calculation time the strain calculation is
performed locally per residue. There is an option to
probe baseline strain increase and thus avoid calculation
loops for unfavorable positioning of the original residue.
The optimization and/or steric clashes can be visualized
in PyMOL (cf. Additional file 4).
Further information
Practical information, such as a user guide and applica-
tion notes, are available at the PyTMs wiki page (http://
www.pymolwiki.org/index.php/Pytms) or by accessing
each function’s specific help, e.g. from the plugin menu.
Users have the option of using either the menu and/or
the Python function that extend the PyMOL API, e.g.
for use in scripts. PyTMs has been developed and tested
using the current PyMOL incentive version 1.7, but is
compatible with version 1.3. Older versions and open-
source PyMOL have minor restrictions, the main one
being the lacking support of custom property ‘p.PTM’
selectors. The overall functionality is, however, otherwise
not affected. Modified models can be saved as ‘.pkl’ files,
which preserve bonds and valences correctly. We antici-
pate that additional PTMs and functionality will be
added as PyTMs becomes updated in due time.
Application examples
Here we provide some basic application examples of
how PyTMs can be employed to address research ques-
tions related to PTMs, which we discuss below in the
Results section:
Enzyme inhibition: nitrated HPR1
The model of hydroxypyruvate reductase 1 (HPR1) from
Arabidopsis thaliana was kindly provided by Dr. Fran-
cisco J. Corpas [43]. The missing nicotinamide adenine
dinucleotide phosphate (NADPH) co-factor was added
from the aligned structural homologue Pyrococcus hori-
koshii hydroxypyruvate reductase [PDB: 2DBQ] and
slightly adjusted to fit the cavity without significant
steric clashes. Using PyTMs, we introduced nitrations of
Tyrosine residues that have previously been experimen-
tally determined to be nitrated [43]. In particular, nitration
of TYR198 close to the active site has been demonstrated
to inhibit enzyme activity. The steric vdW clashes in
HPR and the NADPH co-factor (Figure 2B + C) were
Figure 1 (See legend on next page.)
Warnecke et al. BMC Bioinformatics 2014, 15:370 Page 4 of 12
http://www.biomedcentral.com/1471-2105/15/370
(See figure on previous page.)
Figure 1 Overview. This figure gives an overview over all currently covered PTMs that can be introduced in PyMOL using PyTMs. Top: A table of the
possible modifications in alphabetical order. PTM = post-translational modification. The columns from left to right contain: name of modification, the
PyTMs command that is used to introduce it in the PyMOL API (when not using the GUI menu), a custom property selector name through which the
modification can be selected in PyMOL (requires incentive PyMOL version 1.7 or higher), the target amino acid, information on whether N-termini can
be modified using the respective function (*= modifiable, excluding Proline), a summary of charge effects, a group indicator (see below) and
lastly selected references. Bottom: A depiction of representative modifications from all classes, grouped by amino acid and modification type.
Note that the individual panels A-J correspond to the ‘group below’ column of the above table. All residues are aligned by the amino acid
head, the terminal carboxyl group facing towards the viewer. The base is colored blue and the PTMs in red. Hydrogens are omitted. Groups
are labeled as in the table above. For each category the displayed and total number of variants are indicated. The respective defaults for categories are
underlined. Configurational diastereomers are indicated with the R or S nomenclature.
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‘show_bumps’ (available on the PyMOL wiki), which has
been integrated within PyTMs. This visualization of vdW
clashes can be performed directly in conjunction with
modification. Alternatively, clashes can be visualized in
unmodified protein or retrospectively by using a dedicated
function.SWISS modeling and multiple modifications: oxidation of
hERG1
As the structure of human ether à go-go-related gene 1
(hERG1, KV11.1, KCNH2) is only partially available, we
applied SWISS homology modeling [44] using HCN2-I
[PDB: 3BPZ] [45] as template to generate a joined modelFigure 2 Example – inhibition of HPR1 by nitration. This figure is an applic
the model of hydroxypyruvate reductase 1 from Arabidopsis thaliana was nitrat
the implementation section. This enzyme has previously been demonstrated to
NIY = Nitrotyrosine. A) An overview of the nitrated enzyme monomer is depic
locations of (Nitro-)Tyrosine residues have been highlighted in stick represe
The co-factor (NADPH) in stick representation is colored blue. B + C) A cl
B: native; C: nitrated. Left: Representation as cartoon with the (nitrated) TYR1
discs. The increasing size and redness of the discs correlate with stronger v
clashes. The nitration, however, introduces significant steric clashing wit
as in the left image, but depicted as surface with the extent of the nitra
mainly due to nitration at TYR198, is the structural basis for impaired enof the hERG1 intracellular C-terminal region (residues
667–865), including the C-linker and regulatory domains.
Using PyTMs we oxidized Cysteines and Methionines, ei-
ther in R- or S- configuration, and superimposed the re-
sults for comparison (Figure 3).MAA-modification of Bovine Serum Albumin surface-
exposed lysines
Here we exemplify the integration of PyTMs with sub-
selections and the possibility to predict surface-restricted
modifications, and basic optimization. Pre-selection of
surface-exposed atoms is managed by a cutoff using the
calculated solvent-accessible surface area for each atom.
This pre-selection is set by a user-provided cutoff and isation example of using PyTMs in the setting of enzyme inhibition. Briefly,
ed at three specific Tyrosine residues using PyTMS as described in
be nitrated at these residues and thereby functionally inhibited.
ted in secondary structure cartoon representation. Additionally, the
ntation. The nitro groups in residues 97, 108 and 198 are colored red.
ose-up view of the co-factor (NADPH) binding site in the enzyme.
98. Steric clashes based on vdW overlap are represented by the colored
dW strain. The native enzyme does not have significant steric
h the co-factor and occludes the binding site. Right: identical view
tion colored red. In conclusion, the denied binding of co-factor,
zyme activity.
Figure 3 Example – oxidation of the hERG potassium channel. This figure is an application example of using PyTMs in conjunction with SWISS
modeling, introducing multiple modifications and demonstrating the possibility of modeling stereochemical variants. As the structure of hERG is only
partially resolved, a complete model of the intracellular C-terminal domain of hERG1 (residues 667–865) was generated as described in the implementation
using SWISS modeling. Using PyTMs, this model was then doubly modified by cysteine oxidation and methionine oxidations. Selected residues are
displayed as spheres. Methionine oxidation was performed on object copies introducing either the configurational Methionine sulfoxide R-isomer (red
oxygen) or the S-isomer (yellow oxygen). Note that these configurational isomers are superimposed to highlight the differential positioning and do not
coexist on the same residue. Cysteine oxidation is not racemic (orange oxygen). Oxidation of hERG1, especially at CYS723, has been previously
demonstrated to result in an accelerated deactivation of the associated ion channel. A) An overview of a homo-tetramer of hERG1 intracellular C-terminal
domains, as viewed from above i.e. from the cell membrane or pore. The equivalent monomers are colored either blue or light gray for better distinction.
The viewing positions for C) and D) are indicated. B) This view corresponds to A, but the complex is viewed from the side. Selected residues have been
labeled, as indicated. Note the critical cysteine 723 at the dimer interface. C) A close-up view of the critical oxidized CYS723 at the dimer interface viewed
from outside the complex (cf. A). Note how the polar oxygen extends the range of the cysteine residue to interfere with the adjacent loop (ASP767 and
THR768). Expectedly, a resulting increase in steric displacement can explain the previously reported increase in deactivation rate. D) A close-up view from
inside the complex focusing on adjacent Methionine sulfoxide residues.
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on the PyMOL wiki (‘findSurfaceResidues’). Here, we re-
stricted modification to surface-exposed Lysine epsilon
amine groups in a model of Bovine Serum Albumin
(BSA, [PDB: 4F5S]), using a cutoff of 25 Å2. This cut-
off yielded a reasonable selection of exposed atoms
that were modified using PyTMs. We introduced the
default Malondialdehyde-acetaldehyde (MAA) adduct
(cf. Additional file 3). An optimization level of 3 was
applied to account for potential steric overlap of the
bulky adducts.
Altered peptide ligands – MHC complexes
Crystal structures of the immunodominant lymphocytic
choriomeningitis virus (LCMV)–derived epitope gp34in complex with a murine Major Histocompatibility
Complex (MHC, H-2Kb) have previously been deter-
mined for the native epitope [PDB: 3ROO] and a
nitrated escape variant [PDB: 3ROL] [24]. Starting with
the native unmodified variant we nitrated the peptide
ligand in silico and sterically refined the structure. First
we tested alternative ortho-positions for the nitration
(rotamer of 3-Nitrotyrosine). We thereafter chose alter-
native backbone-dependent rotamers for GLU152 in
the MHC side chain and TYR116 in the beta-sheet of
the MHC heavy chain peptide-binding cleft. These two
adaptations were expected to accommodate the nitro
group without significant steric clashes. Finally, we
aligned the resulting models with the experimentally re-
solved structure containing the nitrated epitope. The
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PyTMs corresponded well to the previously determined
crystal structure [24].
Results and discussion
Straightforward modeling of post-translational
modifications
The purpose of PyTMs is to facilitate modeling of
PTMs. There is a steady interest from various fields in
the impact of PTMs and hence a need for tools that en-
able their prediction and analysis. Although basic struc-
ture editing options are available in the PyMOL base
package, we identified two hurdles. Firstly, manual edit-
ing requires additional user experience and secondly, it
can be laborious even when using libraries. We therefore
set out to facilitate the procedure by developing a
plugin.
We implemented ten different PTMs as listed in
Figure 1. These cover a large ensemble of common
PTMs, all of which are well-studied and implicated ei-
ther in important physiological processes or in disease
settings (cf. Figure 1). Here we provide a selection of ex-
amples and discuss the overall applicability of PyTMs as a
plugin tool.
Application example: enzyme inhibition in nitrated HPR1
We searched the literature for examples of PTMs affect-
ing enzymatic activity. For instance, Corpasa et al. dem-
onstrated that nitration of TYR198 in hydroxypyruvate
reductase 1 from Arabidopsis thaliana results in enzyme
inhibition [43]. Using site-directed mutagenesis the au-
thors confirmed that nitration of TYR198 in the active
site is responsible for the loss of function, but they did
not include nitrations in the structural model. Using the
PyTMs plugin we introduced nitration at the relevant
sites and investigated the model in further detail. Con-
sistent with the previously reported observations, we
demonstrate that nitration of TYR198 obstructs the co-
factor binding site, providing a structural explanation for
reduced enzyme activity (Figure 2).
This example demonstrates that PyTMs can be utilized
to help explain experimental observations on the basis
of a structural model and suggest that it can also be used
to predict such loss of function.
Application example: multiple oxidation of hERG1
The human ether à go-go-related gene 1 hERG1 (KV11.1,
KCNH2) encodes a potassium channel infamous for off-
target drug side-effects that result in cardiac arrhyth-
mias. Structurally hERG1 resembles other members of
hyperpolarization-activated, cyclic nucleotide-modulated
(HCN) channels [45]. The pore-forming transmembrane
domains are connected to an intracellular C-linker re-
gion and a regulatory ligand-binding domain. Both theC-linker and the ligand-binding domain contain residues
that are involved in homo-tetramerization of the intra-
cellular domains. This structured tetramerization is
regarded as the underlying mechanism towards opening
the associated potassium channel upon ligation [45].
The intracellular region, in particular the C-linker, is
sensitive to oxidation of Methionine [46] and/or Cyst-
eine [30] residues. These oxidations account for an ac-
celerated channel deactivation [30,46].
Our extended model in Figure 3 supports the previ-
ously reported conclusions. The generated model sup-
ports a critical role for oxidation of CYS723 at the dimer
interface, which is consistent with a faster deactivation
of hERG1 following oxidation due to increased struc-
tural strain. The same argument holds for Methionine
844. The oxidized MET844 has proximity to the dimer
interface and sterically clashes with ASP774 and LEU775
of the neighboring chain. As MET713 or MET756 do
not have immediate proximity to neighboring subunits,
the inhibitory effect may involve rearrangement of the
associated helices upon oxidation of these residues, and
therefore a more indirect mode of inhibition. Note that
the alternative configurational isomers (R:red, S: yellow)
may have unequal impact in this respect.
Based on this model the critical role of CYS723 in the
susceptibility of hERG1 to oxidation derives from its
open accessibility and positioning at the dimer interface.
The equivalent explanation is valid for MET844. For the
remaining Methionine sulfoxides the inhibition is ex-
pected to be less direct and may involve rearrangement
of the associated C-linker helices. Hence, several Me-
thionine residues may require oxidation to confer the
same degree of inhibition as oxidation of CYS723 or
MET 844 alone.
This example alludes to several modeling aspects.
First, it exemplifies the use of homology modeling [44]
in case a resolved structure is unavailable. Secondly, the
model is an example of introducing several different
PTMs into one protein model. In fact, the only condi-
tion for consecutive modification in silico using PyTMs
is that the target atom is still available. For instance, it is
possible to co-modify an N-terminal Tyrosine by phos-
phorylation, nitration and N-terminal acetylation (see
also graphical abstract, Additional file 5). This may not
necessarily be biologically relevant, as nitration has been
demonstrated to impede subsequent enzymatic phos-
phorylation [47], but this is allowed within the program.
Finally, this example addresses modeling of diastereo-
mers [48]. We implemented biologically relevant diaste-
reomers for Methionine sulfoxide, Cysteine-s-dioxides
and the 2-formyl-3-(alkylamino)-butanal (FAAB frag-
ment) adduct of Malondialdehyde. Hydroxyl-proline is
technically chiral but biologically always present in a 4-R
configuration, since this is an enzymatic modification.
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As diastereomers of Methionine sulfoxide are repaired by
distinct enzymes [38] we suspect that additional biomole-
cules such as antibodies, T-cell receptors, complement
components and scavenger receptors also discriminate
stereospecific variants [48].
Notably, this example also indicates a current limita-
tion of the plugin, namely a disregard for potential glo-
bal conformational changes induced by PTMs. Although
some manual local refinement can be informative, larger
rearrangements will become increasingly artificial and
unreliable. Conformational changes that affect large or
distal areas will be especially problematic. With this in
mind conventional structure determination, although la-
borious, will yield more conclusive results. Here we
point out SWISS modeling [44] as a previously available
resource that can be applicable in case of unavailable
crystal structures.
In summary, it is possible to induce several modifica-
tions in one model and specify stereospecific variants.
The resulting model should, however, not be over-
interpreted as potential global conformational changes
are not handled by the software. Nonetheless, it is pos-
sible to explain experimental data or make predictions at
a detailed structural level using PyTMs when respecting
these caveats.
Application example: MDA-modification of Bovine Serum
Albumin surface-exposed Lysines
A critical factor that influences the likelihood of modifica-
tion is accessibility of the target atom. Non-selective oxi-
dative modifications, such as Malondialdehyde (MDA)
derived from lipid peroxidation, will primarily target the
most accessible residues while buried residues are likely
spared. Using PyTMs we selected only surface-exposed
epsilon-amines (area cutoff: 25 Å2) in a model of BSA and
introduced Malondialdehyde-acetaldehyde (MAA) ad-
ducts. We implemented a basic vdW strain optimization
for this PTM category as many adducts are comparatively
bulky and tend to sterically clash with adjacent residues.
Applying optimization rotates the modified Lysine to a
more favorable rotamer, but requires some calculation
time. We implemented that this optimization can be ani-
mated in PyMOL (cf. Additional file 4). Additional infor-
mation on the implementation of MDA adducts is
provided in the Additional file 2 [48,49].
Figure 4 displays MAA-modified BSA in which the
surface-accessible amines have been modified (75 of 118
Lysines). The pre-selection noticeably restricted modifi-
cation to surface residues while inaccessible Lysines
remained unmodified (Figure 4B). Indeed, buried resi-
dues are most likely protected from modification within
the protein, unless it unfolds in the process. Unlike the
first example, in which the nitrations were detected byMass-Spectrometry prior to modeling, this example is
predictive. Notably, should Mass-Spectrometry detect
modified residues at unexpected locations, this may indi-
cate that the protein becomes unfolded during the modi-
fication process. In relation to topology we were unable
to assess the associated charge impact of modification.
The limitation is currently that force field applications
such as the Adaptive Poisson-Boltzmann Solver (APBS)
[50] currently only support standard amino acids. This
aspect may be addressed in the future, but will require
the generation of custom force fields for PTM amino
acids. Experimental data indicates that increasing MAA
modification gradually eliminates positive charge and
thus alters the migration of proteins in native or isoelec-
tric focusing gels ([36] and data not included).
In summary, we conclude that restricting modification
to experimentally defined or accessible atoms are feas-
ible approaches to improve model accuracy. Optimally,
each model should be generated according to supporting
experimental data at hand or be experimentally validated
accordingly. We point out that PyTMs could for in-
stance be used to introduce missing PTMs for structure
information retrieved from PhosphoSitePlus [27].
Application example: MHC-restricted peptide epitopes
Modifications can be introduced into single amino acids,
peptides or whole proteins using PyTMs. In the context
of altered peptide ligands (APLs) and Major Histocom-
patibility Complexes (MHCs), modeling can be useful to
explain or predict whether an APL can be presentable
by a respective MHC allele and/or how the introduced
PTM and APL may be oriented.
Herein we made use of a pair of crystal structures of
murine H-2Kb MHCs in complex with the lymphocytic
choriomeningitis virus (LCMV)-derived immunodomi-
nant epitope gp34, without or with nitration [24]. The
nitrated APL is an escape variant and exhibits signifi-
cantly reduced binding affinity [24]. Using the native
complex we nitrated the Tyrosine at position 3 in gp34
and performed minor local refinements to accommodate
the APL.
As described in Figure 5D, we concluded that the
orientation of the ortho-position, i.e. the rotamer of
Nitro-tyrosine, is a factor that affects the affinity to the
MHC. Steric clashes dictate that the nitro group only fits
into the groove when facing away from the MHC helix into
the groove. This problem does not occur for the Tyrosine
itself. Furthermore, this positioning requires structural
adaptation of GLU152. Consequently, the hydrogen bond-
ing is altered for the nitrated gp34. The steric displacement
of GLU152 breaks a hydrogen bond between this residue
and the Nitrotyrosine hydroxyl group (Figure 5B). This loss
is partially compensated for by TYR116 and GLN114
forming hydrogen bonds with the nitro group inside the
Figure 4 MAA adducts on the surface of BSA. This figure is an application example of using PyTMs to selectively modify only solvent-accessible
residues. As described, a model of Bovine Serum Albumin (BSA) was used to sub-select surface atoms before introducing Malondialdehyde-acetaldehyde
(MAA) adducts. The brown surface corresponds to the original unmodified BSA. Both unmodified Lysines (43/118) and MAA-Lysines (75/118) are depicted
in stick representation, but colored black or red, respectively. A) An overview of MAA-modified BSA with opaque surface. Note the surface decoration by
MAA adducts (red sticks). B) An identical image with transparent surface. Note how the inaccessible/unmodified Lysines (black sticks without adduct) are
likely to be shielded from modification within the protein’s interior volume. Additional MAA-modified-Lysines from the protein’s distal surface are
also visible.
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the reduced binding capacity observed for the nitrated pep-
tide. A final comparison of the refined model to the
existing crystal structure with nitrated APL exhibited a
striking similarity (Figure 5B vs. 5C).
Furthermore, in Additional file 3 we made use of the
same model but introduced alternative PTMs, namely N-
terminal acetylation (p1ACE-ALA) and/or methionine
oxidation (p8SME). Based on the putative steric clashing
with either the MHC rim (p1ACE-ALA) or the anchoring
pocket (p8SME), we predict that these modifications will
negate binding of the APL to H-2Kb. The acetylated pep-
tide is too long to fit the confinements of the MHC class I
groove, and the anchoring pocket cannot properly accom-
modate the oxidized methionine. In summary, modeling
of MHC-associated APLs is possible and yields predictive
results within a reasonable frame of confidence. Larger
global conformational changes, however, cannot be
accounted for using this approach.We conclude that modeling of APLs can be a useful
approach prior to experimental investments. Further-
more, it can also be applicable to predict whether a
PTM is likely to be in contact with the MHC and/or a
corresponding T-cell receptor.Conclusions
Perspective and future development
To summarize, we have presented several examples of
how modeling using PyMOL and PyTMs can be applied
to straightforwardly address various research questions
related to PTMs. In either predictive or explanatory set-
tings, modeling constitutes a rapid approach to investi-
gate structural implications. The advantages of using a
plugin to introduce PTMs include standardized gener-
ation of PTMs, rapid time-to-result and facilitated user
control. In addition, modeling is an option to maximize
cost-efficiency.
Figure 5 MHC–related applications. In this figure we tested the
applicability of PyTMs with respect to altered peptide ligands (APLs). As
described in the implementation, we started with the crystal structure
of a native gp34 LCMV epitope complexed within the mouse MHC
class I molecule H-2Kb. We introduced nitration into the p3TYR residue
and refined the structure locally to resolve resulting clashes. The results
were aligned and compared to the experimentally determined crystal
structure. A) Orientation of the native gp34 in the resolved crystal
structure [PDB: 3ROO]. The view is focused on the peptide-binding
cleft. B) The refined model of a nitrated gp34 APL derived from the
same crystal structure. Alternative backbone-dependent rotamers for
GLU152 (steric displacement) and TYR116 (hydrogen bonding) have
been chosen to accommodate this APL. C) The aligned gp34 APL and
MHC pocket from the experimentally resolved crystal structure [PDB:
3ROL]. The essential adaptations are surprisingly similar. We therefore
conclude that modeling APLs can be a valid predictive approach.
However, the ligation of this APL induces more pronounced and
global conformational changes that cannot be accounted for by
local refinement. D) Relative positioning of the aligned peptides.
Black and blue: Two nitrated gp34 epitopes according to modeling
which correspond to 180° rotamers of each other. The first variant
(model 1, black) clashed significantly with the helix of the MHC
and TYR159, a feature that may contribute to the reduced affinity
of the nitrated epitope (complete model not shown). The alternatively
positioned model 2 was used for the modeling above and fits
significantly better, especially after local refinement. Note how
the orientation of this APL is essentially identical to that of the
experimentally resolved variant (green).
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namely the incompatibility of non-standard residues
with tested charge force field applications and a limited
ability to assess changes in global conformation. Many
PTMs are associated with drastic alterations in the
charge pattern, rather than steric blocking, citrullination
being a prime example. In concordance with this, con-
formational changes are probably a major mechanism
through which certain PTMs mediate their effects. As
both aspects are limited in PyTMS, this may restrict
the interpretability of resulting models, unless well
supported by experimental observations. Resolving
these shortcomings presents a future challenge. Bear-
ing this in mind, we support the reasonable application
of in silico modeling alongside conventional structure
determination.
In conclusion, PyTMs is a free, user-friendly and very
convenient plugin for PyMOL and can be applied to
straightforwardly address research questions connected
to PTMs. We hope to address the discussed challenges
over time and further extend the applicability with add-
itional PTMs.
Availability and requirements
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Programming language: Python (https://www.python.org/).
Other requirements: PyMOL (http://www.pymol.org/).
License: GNU General Public License, version 2 (GPL-2.0).
Additional files
Additional file 1: PyTMs. The first release version of PyTMs (for deposit
purposes); This file should optimally renamed to pytms.py and placed
inside the ‘plugins’ folder of the ‘PyMOL-script-repo’ when installed. Note
that PyTMs will be updated/maintained on the hompage site: http://
www.pymolwiki.org/index.php/Pytms. Here you should find the latest
version.
Additional file 2: PyTMs supplementary images. Supporting images,
PyTMs menu screenshot and PTM overviews.
Additional file 3: PyTMs supplementary online information.
Supporting information on the implementation of MDA/MAA adducts,
supporting figures.
Additional file 4: This is an example of the residue-based
optimization in PyTMs. The optimization resolves sterical clashes
(represented by red discs) by positioning the adducted residue in a more
favorable position, based on minimal local strain. This examples shows a
test protein (PDB:1hpv) with malondialdehyde-acetaldehyde (MAA) adducts
(red). The animated .gif file can be viewed in a web-browser.
Additional file 5: PyTMs - graphical abstract.png. Graphical abstract. In
this example we modified a generic peptide (MKCRYKWKSTP) to display
a selection of different modifications, as indicated. Colors: original carbons =
white, hydrogens = light grey, nitrogens = blue, oxygens = red, sulfur=
yellow, phosphorus = orange, adducted carbons = dark grey; MDA/
MAA = malondialdehyde/ malondialdehyde-acetaldehyde.
Abbreviations
API: Application programming interface; APL: Altered Peptide Ligand;
MAA: Malondialdehyde Acetaldehyde; MDA: Malondialdehyde; MHC: Major
Histocompatibility Complex; PTMs: Post-translational modifications;
PyTMs: Name of the PyMOL plugin; an analogy to PyMOL and PTMs; TCR: T
cell receptor.
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